Pharmaceutical Rapid Microbiology Testing Market Size to Surpass USD 6.29 Billion by 2034

February 11, 2025 |

1 min read

According to Nova One Advisor, the global pharmaceutical rapid microbiology testing market size is calculated at 1.25 billion in 2024 and is projected to surpass USD 6.29 billion by 2034 with a remarkable CAGR of 17.54% from 2025 to 2034.

Pharmaceutical Rapid Microbiology Testing Market Size 2024 To 2034

Pharmaceutical Rapid Microbiology Testing Market Key Takeaways:

· North America dominated the pharmaceutical rapid microbiology testing market in 2024 and accounted for a market share of 39.0%.

· The reagents & kits segment dominated the market and accounted for the largest share of 45.85% in 2024.

· The instruments segment is expected to grow significantly over the forecast period.

· Growth-based testing held the largest market share of 42.25% in 2024

· Nucleic acid-based testing is projected to witness the highest CAGR of 19.64% from 2025 to 2034.

· Sterility testing held the largest market share of 31.0% in 2024.

· Bioburden assessment segment is expected to grow at the highest CAGR of 19.59% from 2025 to 2034.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/9037

U.S. Pharmaceutical Rapid Microbiology Testing Market Size and Growth 2025 to 2034

The U.S. pharmaceutical rapid microbiology testing market size is evaluated at USD 0.37 billion in 2024 and is projected to be worth around USD 1.84 billion by 2034, growing at a CAGR of 15.69% from 2025 to 2034.

U.S. Pharmaceutical Rapid Microbiology Testing Market Size 2024 To 2034

North America dominated the pharmaceutical rapid microbiology testing market in 2024 and accounted for a market share of 39.0%. The market growth in the region is attributed to the high demand for advanced testing technologies, robust regulatory frameworks, and a well-developed pharmaceutical industry. Furthermore, the increasing focus on patient safety, personalized medicine, and biologics further supports the demand for reliable and efficient solutions, driving the market growth in the region.

A blue pie chart with text

AI-generated content may be incorrect.

The U.S. Pharmaceutical Rapid Microbiology Testing Market Trends

The U.S. is dominated the market growth in 2024. The market growth in the U.S. is attributed to the increasing need for advanced microbial testing in personalized medicine, vaccines and biologics, increasing focus on innovation and growing pharmaceutical industry.

Asia Pacific Pharmaceutical Rapid Microbiology Testing Market Trends

The Asia Pacific is expected to grow fastest during the forecast period. The market growth in the region is driven by increasing regulatory pressure to ensure product quality, coupled with rising production of vaccines and biologics. China, India, Japan, and South Korea are the major countries investing heavily in research and manufacturing.

China Pharmaceutical Rapid Microbiology Testing Market Trends

China is the fastest country in this market. The market is growing rapidly due to the growing pharmaceutical industry. There is an increased need for efficient microbial testing solutions, with the growing demand for biologics and vaccines and significant investments in drug manufacturing and research. Additionally, the evolving emphasis and regulatory framework on improving product safety and quality are further expected to drive market growth in China.

The pharmaceutical rapid microbiology testing market deals with types of technologies that are useful to get microbiology test results faster as compared to traditional culture-plate methods. Microbiology is termed the branch of medical science that deals with the prevention, diagnosis, and treatment of infectious diseases. The increasing awareness about the importance of microbiological testing for product safety and public health and emerging infectious diseases are expected to drive the market growth.

One of the major opportunities driving the growth of the pharmaceutical rapid microbiology testing market is point-of-care testing and expanded applications. The development of user-friendly and portable rapid microbiology testing devices for point-of-care diagnostics provides major growth. These devices can be used in doctor’s offices, clinics, and even more settings. In addition, rapid microbiology testing methods can find applications beyond their current use in industries such as environmental monitoring, healthcare, pharmaceuticals, and food. There is also potential growth in areas such as agriculture, personal care products, and cosmetics.

Artificial intelligence can play an important role in improving pharmaceutical rapid microbiology testing. The integration of AI in microbiology testing can improve epidemiological monitoring, antibiotic resistance prediction, drug development, and disease management. AI systems can enable early detection of antibiotic resistance and accurately and quickly detect infections, such as new and drug-resistant strains. By providing more precise and current findings, AI revolutionized the pharmaceutical rapid microbiology testing market.

Market Trends

· Increasing demand for food safety: To ensure quality and safety, the food and beverage industry has a growing need for rapid microbiology testing methods. Product recalls have heightened awareness of the importance of microbiological testing in this market.

· Rising technological advancements: The rising advances in technology, such as miniaturization, automation and the development of innovation detection methods have made rapid microbiology testing more reliable, faster and accessible, which further expected to drive the growth of the pharmaceutical rapid microbiology testing market.

Pharmaceutical Rapid Microbiology Testing Market Report Scope

Report Attribute	Details
Market size value in 2025	USD 1.47 Billion
Revenue forecast in 2034	USD 6.29 Billion
Growth rate	CAGR of 17.5$% from 2025 to 2034
Actual data	2018 - 2024
Forecast period	2025 - 2034
Quantitative units	Revenue in USD million/billion and CAGR from 2025 to 2034
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Product, Technique, Application, Region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; Saudi Arabia; UAE; South Africa; Kuwait
Key companies profiled	Thermo Fisher Scientific Inc.; Merck KGaA; BD; bioMérieux; Danaher; Sartorius AG; Abbott; QuidelOrtho Corporation; Charles River Laboratories; Rapid Micro Biosystems, Inc.
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Segment Insights

By Product Insights

The reagents & kits segment dominated the market and accounted for the largest share of 45.85% in 2024. These products play an important role in regulatory compliance, quality control and microbial detection. These consumables ensure accurate and consistent results and are necessary for various rapid testing methods, such as immunoassays, ATP bioluminescence and PCR. In addition, the increasing demand for reagents in routine testing, paired with advancements in automation and assay technologies are expected to increase the segment demand.

The instruments segment is expected to grow fastest during the forecast period. The growth in segment in the market is attributed to the increasing demand for precision, efficiency, and automation in microbial testing. Advanced instruments, such as rapid microbiology detection systems, bioluminescence readers, and automated PCR machines, reduce human error and offer faster results. In addition, rising innovations in instrument design, the rise of biology, and the increasing need for strict regulatory compliance are further anticipated to drive the segment growth.

By Technique Insights

Growth-based testing held the largest market share of 42.25% in 2024. Due to the widespread use in environmental monitoring, bioburden and sterility and established regulatory acceptance and reliability, the segment growth is increasing rapidly. Due to the ability to detect a wide range of microorganisms, growth-based techniques, such as direct inoculation and membrane filtration, remained the industry standard.

Nucleic acid-based testing is projected to witness the highest CAGR of 19.64% from 2025 to 2034. The segment growth in the market is attributed to the increasing high speed, accuracy and sensitivity in detecting microbial contamination. In addition, the increasing adoption of cell and gene therapies, personalized medicine and biologics is further anticipated to drive the segment growth.

By Application Insights

Sterility testing held the largest market share of 31.0% in 2024 The segment growth in the pharmaceutical rapid microbiology testing market is driven by increasing production of biologics, parenteral drugs and cell and gene therapies. Furthermore, advancements in rapid sterility testing methods, such as ATP bioluminescence and membrane filtration, enhanced compliance, accuracy and efficiency.

A pie chart with numbers and text

AI-generated content may be incorrect.

Bioburden assessment segment is expected to grow at the highest CAGR of 19.59% from 2025 to 2034. The growth in the market is attributed to the increasing demand for contamination control in non-sterile pharmaceutical products. Additionally, the rising advancements in rapid bioburden testing methods, such as automated systems and ATP bioluminescence, enhance accuracy and efficiency, further driving the market growth.

Immediate Delivery is Available | Get Full Report Access@ https://www.novaoneadvisor.com/report/checkout/9037

Related Report

· Food Safety Testing Market - https://www.precedenceresearch.com/food-safety-testing-market

· Pharmaceutical Analytical Testing Market- https://www.precedenceresearch.com/pharmaceutical-analytical-testing-market

· Preterm Birth and PROM Testing Market- https://www.precedenceresearch.com/preterm-birth-and-prom-testing-market

· Microbiology Testing Market- https://www.precedenceresearch.com/microbiology-testing-market

· Drug of Abuse Testing Market- https://www.precedenceresearch.com/drug-of-abuse-testing-market

Some of the prominent players in the pharmaceutical rapid microbiology testing market include:

· Thermo Fisher Scientific Inc.

· Merck KGaA

· BD

· bioMérieux

· Danaher

· Sartorius AG

· Abbott

· QuidelOrtho Corporation

· Charles River Laboratories

· Rapid Micro Biosystems, Inc.

Pharmaceutical Rapid Microbiology Testing Market Recent Developments

· In January 2024, Rapid Micro Biosystems announced the expected mid-2024 launch of its Growth Direct Rapid Sterility application. This innovation delivers organism detection in 12 hours and final results in 1-3 days, significantly improving upon traditional 14-day methods and offering an advantage over current rapid sterility solutions.

· In May 2023, Charles River Laboratories International, Inc. introduced Accugenix Next Generation Sequencing (NGS) for bacterial and fungal identification. This technology analyzed millions of DNA fragments from a sample, offering pharmaceutical and personal care manufacturers enhanced microbial control insights.

· In July 2022, Merck, a leading science and technology company, announced the launch of its first Microbiology Application and Training (MAT) Lab in Jigani, Bengaluru. The lab aimed to provide facilities and technical expertise to support the development of microbial quality control capabilities within India's life sciences community.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the pharmaceutical rapid microbiology testing market

By Product

· Instruments

· Reagents & Kits

· Accessories

By Technique

· Growth-based Testing

· Nucleic Acid-based Testing

· Cellular Component-based Testing

· Viability-based Testing

· Other Techniques

By Application

· Raw Material Testing